Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-036712
Filing Date
2025-03-10
Accepted
2025-03-10 20:32:03
Documents
1
Period of Report
2025-03-06

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5754
  Complete submission text file 0000950170-25-036712.txt   7180
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Bedrosian Camille L (Reporting) CIK: 0001326969 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41199 | Film No.: 25725534

Mailing Address 43 THORNDIKE STREET CAMBRIDGE MA 02141
Business Address 43 THORNDIKE STREET CAMBRIDGE MA 02141 617-683-0917
Amylyx Pharmaceuticals, Inc. (Issuer) CIK: 0001658551 (see all company filings)

EIN.: 464600503 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)